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Abstract
Background: The Plasmodium falciparum PfA-M1 aminopeptidase, encoded by a single copy gene, displays a neutral
optimal activity at pH 7.4. It is thought to be involved in haemoglobin degradation and/or invasion of the host cells.
Although a series of inhibitors developed against PfA-M1 suggest that this enzyme is a promising target for therapeutic
intervention, the biological function(s) of the three different forms of the enzyme (p120, p96 and p68) are not fully
understood. Two recent studies using PfA-M1 transfections have also provided conflicting results on PfA-M1 localization
within or outside the food vacuole. Alternative destinations, such as the nucleus, have also been proposed.
Methods: By using a combination of techniques, such as cellular and biochemical fractionations, biochemical
analysis, mass-spectrometry, immunofluorescence assays and live imaging of GFP fusions to various PfA-M1
domains, evidence is provided for differential localization and behaviour of the three different forms of PfA-M1 in
the infected red blood cell which had not been established before.
Results: The high molecular weight p120 form of PfA-M1, the only version of the protein with a hydrophobic
transmembrane domain, is detected both inside the parasite and in the parasitophorous vacuole while the
processed p68 form is strictly soluble and localized within the parasite. The transient intermediate and soluble p96
form is localized at the border of parasitophorous vacuole and within the parasite in a compartment sensitive to
high concentrations of saponin. Upon treatment with brefeldin A, the PfA-M1 maturation is blocked and the
enzyme remains in a compartment close to the nucleus.
Conclusions: The PfA-M1 trafficking/maturation scenario that emerges from this data indicates that PfA-M1,
synthesized as the precursor p120 form, is targeted to the parasitophorous vacuole via the parasite endoplasmic
reticulum/Golgi, where it is converted into the transient p96 form. This p96 form is eventually redirected into the
parasite to be converted into the processed p68 form that is only marginally delivered to the parasite food
vacuole. These results provide insights on PfA-M1 topology regarding key compartments of the infected red blood
cells that have important implications for the development of inhibitors targeting this plasmodial enzyme.
Background
Human malaria is the most important parasitic disease
in the tropical countries in terms of morbidity and mor-
tality [1]. The disease is caused by obligate intracellular
protozoan parasites belonging to the genus Plasmodium
and the species Plasmodium falciparum is responsible
for the most severe forms of the disease and most of the
mortality.
To maintain their intracellular mode of life in erythro-
cytes, Plasmodium spp. express a number of proteases
that are involved in invasion processes, the acquisition
and digestion of nutrients from the host cell, and that
facilitate the exit of the parasite at the end of its intra-
erythrocytic stage of development [2,3]. These proteins
with different molecular functions, substrate specificities,
and different cellular localizations have different physio-
logical requirements for their activities. The P. falci-
parum zinc aminopeptidase, PfA-M1, displays a neutral
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7.4, and remaining at least 40% active from pH 5.8 to
pH 8.6 [4]. Initially described in the trophozoite and
schizont stages of the FcB1 strain of P. falciparum, PfA-
M1 was shown by immunofluorescence studies to have
a changing localization pattern during the course of the
parasite development. In trophozoites, the PfA-M1
labelling was diffuse in the parasite cytoplasm with
accumulations outside the digestive vacuole. In schi-
zonts, it turned progressively to a vesicle-like pattern
ending as a clear spot in released merozoites [4]. PfA-
M1 was, therefore, thought to be involved either in the
terminating steps of haemoglobin breakdown, that have
been shown to take place outside the food vacuole [5],
or in the egress from red blood cell/reinvasion process
[ 4 ] .E n c o d e db yas i n g l ec o p yg e n eo nc h r o m o s o m e1 3 ,
PfA-M1 was first described to be a 1,056 amino acid
enzyme displaying canonical signatures of the M1 family
of metallopeptidases and a putative microbodies target-
ing signal at its C-terminus [6]. However, the released
P. falciparum genome [7] predicted a gene model pro-
posing that this protein also has a sequence extension at
its N-terminus, which includes a putative N-terminal
hydrophobic domain (see MAL13P1.56 in the PlasmoDB
database and EMBL Y09081.2). Whether this hydropho-
bic domain behaves like a signal sequence or a signal
anchor has never been addressed experimentally and
may not be clearly predicted since different algorithms
have yielded conflicting predictions [8-11]. Protease
inhibitor treatment or exclusion during parasite harvest,
protein isolation and purification, and the use of poly-
clonal antibodies specific for two peptide domains
(MAP1 and MAP2) deduced from the gene, have
detected three soluble forms of this enzyme designated
p120, p96 and p68, respectively [4,6] (Additional file 1).
Although all three forms contain the complete active
site, the aminopeptidase activity could only be experi-
mentally associated with pure p96 and pure p68 forms,
because the p120 form could only be isolated in pre-
sence of protease inhibitors [4]. Conversely, the p96
form was obtained exclusively from parasites prepared
in absence of protease inhibitors, and was, therefore,
proposed to be an in vitro degradation product of p120
[4]. In parasites released after saponin lysis of infected
red blood cells (iRBCs) in the presence of protease inhi-
bitors, both the p120 and the p68 forms were identified
and equivalent amounts of p120/p68 were found in both
trophozoites and schizonts; early rings (six hours post-
invasion) being devoid of either form of PfA-M1 [4].
The p120 and p68 forms were then proposed to be the
two native forms of PfA-M1, both found in saponin-iso-
lated parasites. These results did not conclusively
address the question on how PfA-M1 biosynthesis and
maturation occurs during the intra-erythrocytic cycle of
P. falciparum, since two cleavages - one upstream and
o n ed o w n s t r e a mo ft h ee n z y m ea c t i v es i t e-a r en e c e s -
sary to yield p68 from p120 (see Additional file 1).
These results also left open the question as to whether
p120, p96, and p68 played any distinct functional role in
the biology of the parasite [4].
In this report, the biosynthesis and maturation of PfA-
M1 during the P. falciparum erythrocytic cycle was
further investigated by focusing on the presence of the
different forms in distinct compartments of the infected
red blood cells.
Methods
Materials
Streptolysin O (SLO) was a kind gift from Sucharit
Bhakdi (University of Mainz, Germany). Saponin was
purchased from Fluka. Sequence-grade modified trypsin
was purchased from Promega (Madison, WI, USA). All
the other chemicals, including Brefeldin A (BFA), were
of the highest available purity and were purchased from
Sigma-Aldrich.
Parasite cultures and fractionation of iRBC
Parasites (FCBR strain of P. falciparum [12]) were con-
tinuously cultured in erythrocytes of blood group A
+ in
heat inactivated human serum as described previously
[13]. Cultures were synchronized and trophozoite
infected erythrocytes (iRBC), 28-30 hours post infection,
were enriched to a parasitaemia of more than 90% by
gel flotation [14]. IRBC were permeabilized with SLO as
described previously [15]. Briefly, 1 × 10
9 iRBC (in ali-
quots of 2 × 10
8 cells) were incubated with 3-4 haemo-
lytic units of SLO in PBS pH 7.2 at room temperature
for 6 min. Samples were centrifuged at 10,000 × g for
15 s. The pellet containing intact parasites, the vacuolar
contents, and membranes was washed twice with 200 μl
of PBS. The removal of haemoglobin was monitored
spectrophotometrically as described previously [15]. For
saponin lysis, 1 × 10
9 iRBC (in aliquots of 2 × 10
8 cells)
were incubated in 200 μl of 0.1% saponin in PBS pH 7.2
on ice for 5 min. The samples were centrifuged at
2,500 × g for 5 min. The pellet containing the intact
parasite devoid of the host cytosol and PV contents was
washed twice with 200 μl of PBS before processing for
further analysis by SDS-PAGE and western blot. To pre-
vent proteolysis by endogenous proteases, all the buffers
used in this section contained a protease inhibitor cock-
tail (PIC) consisting of antipain, chymostatin, aprotinin,
trypsin inhibitor, Na-EDTA, pepstatin, leupeptin, and
elastatinal, each at a concentration of 1 μg.ml
-1.
Stage specific expression experiments
Parasite cultures (FCBR strain) were synchronized and
trophozoite-infected erythrocytes (iRBC), 28-30 hours
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than 90% by gel flotation [14]. Aliquots equivalent to
2×1 0
8 iRBC were used to initiate new 5 ml cultures.
After reinvasion these cultures were synchronized by
alanine treatment [16] to obtain tightly synchronized
parasite stages. The parasites were harvested 6-12 hours,
18-24 hours, 30-36 hours and 38-44 hours post-inva-
sion. 2 × 10
7 equivalent amounts of the parasites from
each set time point were lysed in SDS-PAGE sample
buffer before analysis by SDS-PAGE and western blot.
All the buffers used in this section contained the pro-
tease inhibitor cocktail (PIC).
Recombinant p68 form and production of specific anti-
p68 antibodies in mice
T h er e g i o ne n c o d i n gt h ep 6 8f o r mo fP f A - M 1w a s
amplified by using Forward 5′-ACGG A TC C TG T T
AAA AAG AAC GAA CC-3′ and Reverse 5′-ATGG A T
CCA TTG TGC ATT TAC TGG TG-3′ primers
(BamHI site in bold and underlined) and inserted into
the BamHI site of pET-15b (Novagen). The recombinant
plasmid was sequenced to confirm the correct reading
frame and the absence of mutation. It encodes a
N-terminal (His)6-tagged protein, corresponding to
residues 191 to 802 of PfA-M1. This (His)6-p68 recom-
binant protein was produced in BL21(DE3) Escherichia
coli as described [17], but was not soluble. It was iso-
lated, by using BugBuster™ (Novagen) in presence of 6
M urea according to manufacturer’s instructions and
purified on nickel-affinity columns, in presence of urea.
The eluted fractions containing recombinant (His)6-p68
were dialyzed against 10 mM HEPES NaOH pH 8.0 to
remove urea and concentrated on Centriprep10 (Ultra-
filtration device, Millipore) prior to being used to immu-
nize three mice. Mice were injected four times with the
purified-recombinant (His)6-p68 at three weeks intervals,
the first injection being performed with complete
Freund’s adjuvant and the next three injections with
incomplete Freund’s adjuvant. The three mice produced
antibodies specifically labelled p68, but also p96 and
p120, as determined by immunoblotting.
2D-gel electrophoresis for the comparative analysis of
anti-MAP1 and anti-p68 antibodies
Parasites (FcB1 strain of P. falciparum)w e r ec u l t u r e d
but not synchronized, and isolated by using 0.1% sapo-
nin as previously described [4]. Purified parasites were
lysed in 0.1 mM Tris-HCl pH 7.5 by three cycles of
freezing/thawing in presence of protease inhibitors
(Complete™ EDTA-free (Boehringer Mannheim) and
2 mM EDTA) as previously described [4], and separated
into soluble and membrane fractions by ultra-centrifuga-
tion (100,000 × g for one hour). 100,000 g soluble
extracts were concentrated by using kit-2D clean up
(GE Healthcare), and identical amounts (70 μg proteins)
were used to rehydrate two identical 3-10 strips (GE
Healthcare) in the presence of 8.75 M urea, 2.5 M
thiourea, 5% CHAPS, 3.5 mg.ml
-1 DTT and 2% ampho-
lytes (GE Healthcare). After electrofocusing, the two
strips were equilibrated 15 minutes in 6 M urea, 50 mM
Tris-HCl pH 8.8, 70 mM SDS, 34.5% Glycerol and 65
mM DTT then 15 minutes in 6 M urea, 50 mM Tris-
HCl pH 8.8, 70 mM SDS, 34.5% Glycerol and 130 mM
iodoacetamide, before being placed side by side on a
single large 7%-SDS-PAGE. The SDS-PAGE was run
and processed for immunoblot analysis, as described in
the corresponding section.
Brefeldin A treatment of parasites
Parasites (FcB1 strain of P. falciparum)w e r ec u l t u r e d
and synchronized as previously described [4] in the pre-
sence of 367 μM hypoxanthine to obtain a population of
early rings (one to six hours post-invasion) that was
divided into three identical cultures (B, E and O, with
about 5 × 10
8 iRBC each). Brefeldin A (BFA) was added
to B at a final concentration of 5 μM (about 1.5 μg.ml
-1)
from a 5 mg.ml
-1 solution in ethanol as previously
described [18]. Control cultures received (E) or not (O)
equivalent amount of ethanol to ensure that ethanol had
no effect on growth and cell morphology. These three
cultures were further incubated for 19 hours prior to
parasite harvest and preparation by using 0.1% saponin
as described [4]. Purified parasites were lysed in 0.1 mM
Tris-HCl pH 7.5 by three cycles of freezing/thawing and
analysed by SDS-PAGE and immunoblotting as
described in the corresponding section.
Immunofluorescence analysis of parasites
In parallel, aliquots of BFA-treated and control cultures
were smeared on slides and fixed for 5 min in a mixture
of methanol and acetone (1:4) at -20°C. Slides were
washed in PBS, blocked at room temperature in non-fat
milk (5% in PBS) then incubated for two hours at room
temperature with anti-MAP1 antibodies as previously
described [4]. Slides were then washed again three times
in PBS and incubated for two hours at room tempera-
ture with mouse anti-exp2 [19] antibodies. After three
further washes in PBS, slides were incubated with a mix-
ture of anti-rabbit-Ig coupled to Alexa-fluor-568 and
anti-mouse-Ig coupled to Alexa-fluor-488 secondary
antibodies (Molecular Probes). Nuclei were labelled by
10 min incubation with 4 μg.ml
-1 Hoechst 33342 (Mole-
cular Probes). Slides were mounted in Vectashield med-
ium (Vector laboratories) with a coverslip and viewed
using a Nikon Eclipse TE 300 DV inverted microscope
with a 100× (NA 1.3) oil objective mounted on a piezo
electric device using appropriate fluorescence emission
filters. Image acquisition was performed using a
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images were finally processed by using Metamorph
software.
Isolation of intact food vacuoles
To isolate intact food vacuoles parasites were fractio-
nated as previously described with minor modifications
[3,20]. Briefly 10
9 iRBC were washed three times with
PBS and permeabilized with SLO as described pre-
viously. The iRBC (in aliquots of 2 × 10
8 cells) were
incubated with 3-4 haemolytic units of SLO in PBS pH
7.2 at room temperature for 6 min. Samples were centri-
fuged at 10,000 × g for 15 s. The pellet containing intact
parasites, the vacuolar contents, and membranes was
washed twice with 200 μlo fP B S .T or e l e a s et h ef o o d
vacuoles the pellet was lysed by resuspension in 10
volumes of ice-cold water, pH 4.5, and immediately tri-
turated four times using a 27-G 1.2 cm needle. The
mixture was centrifuged at 13,000 rpm for 10 min to
obtain the soluble proteins (A) and a pellet containing
membranes and vacuoles. The crude vacuole prepara-
tion was washed with 10 volumes of ice-cold water, pH
4.5 centrifuged at 13,000 rpm for 2 min and the super-
natant was analysed (B) to monitor the distribution of
marker proteins. The pellet was resuspended in 1 ml of
uptake buffer (2 mM MgSO4, 100 mM KCl, 10 mM
NaCl, 25 mM HEPES, 25 mM NaHCO3,a n d5m M
sodium phosphate pH 7.4, containing 5 mg.ml
-1 of
DNase 1), and incubated at 37° C for 5 min followed by
centrifugation for 2 min at 13,000 rpm. The supernatant
was discarded and the pellet was again resuspended in
100 μL of ice-cold uptake buffer and mixed with 1.3 ml
of ice-cold 42% Percoll™ containing 0.25 M sucrose and
1.5 mM MgSO4, pH 7.4. The suspension was triturated
2 times through a 27-G 1.2-cm needle before centrifuga-
tion at 13,000 rpm for 10 min at 4°C. The fractions C,
D, E, and F were obtained after the centrifugation step.
Purified vacuoles (E) were collected as a dark band at
the bottom 50 μL of the gradient. The vacuoles were
then resuspended in 1 mL of uptake buffer, and centri-
fuged at 13,000 rpm for 2 min to wash off the residual
Percoll™ before proceeding with immunoblot analysis
using an equivalent of 4 × 10
7 iRBC per lane. All the
buffers used in this section contained the protease inhi-
bitor cocktail (PIC).
Western blot analysis
Proteins separated by SDS-PAGE were transferred to
nitrocellulose membranes using standard procedures. To
detect the presence of PfA-M1 [4,6] and the other mar-
ker proteins (PfAldolase [15], PfBip [21], PfPV1 [22],
PfPlasmepsin I [23], PfSERP [18]), the membranes were
blocked with 3% BSA in PBS, pH 7.4, for 1 h at room
temperature before overnight incubation at 4°C with the
primary antibodies. After the overnight incubation the
membranes were washed three times with 10 mM Tris-
HCl, pH 7.4, 150 mM NaCl before incubating with the
secondary antibody, anti rabbit IgG conjugated with
horseradish peroxidase (FCBR strain) or anti rabbit IgG
conjugated with alkaline phosphatase (FcB1 strain) for
one hour. The proteins bands were visualized using the
ECL (FCBR strain) or nitroblue tetrazolium/5-bromo-4-
chloro-3-indol phosphate (FcB1 strain).
Stable transfection of P. falciparum with a PfA-M1-GFP
construct
The plasmid pPM2GT, used to stably transfect plasmep-
sin II-GFP into Plasmodium [24], kindly provided by Dr.
Klemba, was modified as follows: the plasmepsin II gene
segment encoding the C-terminal end of the protease
was excised by using the AvrII and XhoI sites and was
replaced by a 1024-bp segment encoding the C-terminal
part of PfA-M1. To amplify this PfA-M1 gene segment,
we used the Forward 5′-GCA CGCT C GA G TA A T
TAT TAT TGA AAT ATG ATA GTG ATG C-3′(AvrII
site in bold) and Reverse 5′-GCA CGCC T AG G TA A T
TTA TTT GTT AAT CTT AAT AAA TAT TC-3′(XhoI
site in bold) primers. The recombinant plasmid was
sequenced to confirm the correct reading frame and the
absence of mutation before transfection into the FcB1
strain of P. falciparum according to [25]. Transfected
parasites were selected using 10 nM WR99210 as
described in [24] and the selective pressure was removed
and applied again to isolate pseudo-clonal parasites
named PfA-M1-GFP-51. These parasites, which are very
similar to the PfA-M1-YFP parasites generated by [26]
were analysed by southern blotting to confirm proper
integration of the plasmid, immunoblotting to visualize
the recombinant protein and fluorescence imaging to
localize the GFP fluorescence. Live imaging was per-
formed on parasites stained with 4 μg.ml
-1Hoechst
33342, using the Nikon Eclipse TE 300 DV inverted
microscope, the Coolsnap HQ camera and the Meta-
morph software for image processing, as described
above for the immunofluorescence imaging.
Transient transfection of P. falciparum with a PfA-M1 [1-
30]-GFP construct
The PfA-M1 [1-30]-GFP plasmid was constructed using
Multisite Gateway™ technology described by van Dooren
et al [27]. Briefly, the Multisite Gateway™ is based on
specific recombination of pENTR plasmids called pro-
moter vector, gene vector and reporter vector with a
destination vector. Promoter vector (PfHSP86), reporter
vector (GFP mut2) and destination vector (hDHFR cas-
sette conferring resistance to WR99210 [28]) were kind
gifts of G. van Dooren and G. MacFadden. The gene
vector specific for the first 30 amino acids of PfA-M1
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ment (on P. falciparum genomic DNA) using Forward
5′-CAC CAT TAC AAA ATG AAA TTA ACA AAA
GGC TG-3′ and Reverse 5′-GCA CCT TTT TTT ATT
ATC ATA AAG AAT-3′primers and inserting the seg-
ment into pENTR™D/Topo® (Invitrogen). The recombi-
nant plasmid was produced following the Multisite
Gateway™ technology (Invitrogen) as described [27] and
sequenced to confirm the correct reading frame and the
absence of mutation. P. falciparum (FcB1 strain) para-
sites were then transfected with this plasmid and trans-
fectants were selected using 5 nM WR99210 as
described [27]. Transfectants were analysed by immuno-
blotting and live imaging as described above.
Results
Antibodies raised to the p68 form of PfA-M1 confirm the
three p120, p96 and p68 forms of PfA-M1
PfA-M1 was previously reported to be present in three
soluble forms named p120, p96, and p68 by using two
anti-peptide antibodies anti-MAP1 and anti-MAP2 [4].
To confirm that no additional form of PfA-M1 exists in
the parasite, antibodies were raised against a recombi-
nant protein corresponding to the p68 form and were
used to immunoblot parasite extracts separated by 1D
or 2D-gel electrophoresis (Additional file 2). Identical
patterns are revealed using either anti-p68 or anti-
MAP1 antibodies, thus confirming that these three
forms are the only PfA-M1 soluble forms found in
P. falciparum red blood cells. Moreover, immunoblot
analyses of parasite membrane fractions indicated that
among these three forms, only p120 was, in part, asso-
ciated with membrane fractions while p96 and p68 were
strictly soluble (see below).
The p120 form of PfA-M1 is expressed in ring stages at
least 12 hours before p68 is detected
PfA-M1 was previously shown to be expressed in tro-
phozoites and schizonts with no expression in early
rings (0-6 hours post-invasion) [4], but its transcrip-
tomic profiles later suggested that it could be expressed
in more mature rings [29,30]. A time course study was
performed indicating not only that PfA-M1 was indeed
expressed as early as 6-12 hours (post invasion) but
that, at this stage, only the p120 form was found in
parasites (Figure 1, lane 2). The p68 form was absent.
At 18-24 hours post infection, both the p120 and the
p68 forms were present and these persisted to the end
of the cycle, in agreement with the earlier observations
[4]. Traces of p96 were also detected at 18-24 and 30-36
hours post infection (Figure 1, lanes 3 and 4). These
results indicate that p120 is expressed in parasites before
the appearance of p96 and p68, and the less abundant
form of p96 is mainly observed in mid-stages parasites.
PfA-M1 is also present in the parasitophorous vacuole
A proteomic study of the parasitophorous vacuole (PV)
was previously performed revealing numerous proteases
and chaperones but not PfA-M1 [22]. In further ana-
lyses, the PV proteome has been further investigated by
using other more sensitive proteomics approaches
including Difference In Gel Electrophoresis (DIGE) after
differential fractionation of infected erythrocytes with
streptolysin O, saponin, and LC-MS-MS. Using this
DIGE approach and peptide mass fingerprinting it was
possible to identify PfA-M1 with high sequence cover-
age, and the identified peptides covered almost the
entire length of the protein with the exception of the
N-terminal hydrophobic domain and the C-terminus of
Figure 1 PfA-M1 is expressed under the p120 form before the apparition of p96 and p68. The expression of the p120, p96, and p68
forms of PfA-M1 is stage specific. Soluble parasite extracts from: non infected erythrocytes (lane 1); infected erythrocytes 6-12 hours post
invasion (lane 2); infected erythrocytes 18-24 hours post invasion (lane 3); infected erythrocytes 30-36 hours post invasion (lane 4); infected
erythrocytes 38-44 hours post invasion (lane 5), were blotted with anti-MAP1 antibodies [6] to detect PfA-M1 (A) and anti-Pf Aldolase antibodies
(B) [15] as control. The p120 is expressed early in the erythrocytic stages and it is detectable at 6-12 hours post invasion (lane 2). The amount of
p120 increases to a maximum at 38-44 hours post invasion (lane 5). In contrast p68 is not detected 6-12 hours post invasion (lane 2) but is
appearing 18-24 hours post invasion (lane 3). Traces of p96 are observed at 18-24 hours and 30-36 hours post invasion (lanes 3 and 4).
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data suggested that PfA-M1 is present in the PV lumen.
To validate these observations and to determine which
forms of PfA-M1 were present in the PV lumen, the pore
forming toxin streptolysin O (SLO) and the detergent
saponin (SAPO) were used on identical samples of syn-
chronized trophozoite stage P. falciparum infected red
blood cells (iRBC). SLO releases soluble erythrocyte com-
ponents but leaves the parasitophorous vacuole membrane
(PVM) intact while saponin disrupts the erythrocyte mem-
brane and the PVM thus releasing the contents of the
parasitophorous vacuole [15]. Using antibodies directed
against marker proteins for defined compartments within
the infected erythrocytes (PfPV1, a marker of parasito-
phorous vacuole [22]; PfBip, a marker of the parasite
endoplasmic reticulum (ER) [21] and PfAldolase, a marker
of the parasite cytosol; [15]) it was confirmed that SLO
permeabilization did not affect the integrity of the PVM
(the soluble proteins of the parasitophorous vacuole,
PfPV1 is absent from lane 1, Figure 2B). In this assay, the
control parasite PfBip and PfAldolase as well as PfA-M1
were not released into the supernatant fraction (they are
absent from lane 1, Figure 2A, C, D). Conversely, the 0.1%
saponin treatment released soluble proteins of the parasi-
tophorous vacuole (such as PfPV1, lane 4, Figure 2B)
without affecting internal parasite proteins (PfBip and
PfAldolase, lane 4, Figure 2C, D). Interestingly, this 0.1%
saponin treatment also released a proportion of p120 form
of PfA-M1 (lane 4, Figure 2A) confirming its presence in
the PV. The p68 form of PfA-M1 remained exclusively
within the parasite, together with an internal population of
the p120 (lane 5, Figure 2A). Note also that only p120 is,
in part, associated with membrane fractions (Figure 2A,
lanes 3 and 6). These results show that PfA-M1 is not
translocated beyond the parasitophorous vacuole mem-
brane to the cytoplasm of the infected red blood cell. In
addition, PfA-M1 does not contain PEXEL, VTS, or the
HTS sequences or motifs that have been proposed to be
responsible for the targeting of parasite proteins across the
PVM into the erythrocyte cytosol [31,32]. However, PfA-
M1 appears to have the capacity to be exported or
secreted into the parasitophorous vacuole, most likely by
using its N-terminal hydrophobic domain which has been
shown to act as a recessed signal sequence in some other
P. falciparum proteins [33].
Brefeldin A blocks the p120 form of PfA-M1 near the
nucleus
Brefeldin A (BFA) is a fungal metabolite that specifically
inhibits anterograde transport from the ER to Golgi in
Figure 2 The p120 form of PfA-M1 is present in the PV space. Identical amounts of synchronized trophozoite stages were treated with
streptolysin O (SLO) (lanes 1, 2, 3) or 0.1% saponin (SAPO) (lanes 4, 5, 3) as described in the Methods section. Lane 1 corresponds to SLO
supernatant (SNT) i.e. the cytoplasm of iRBC while lane 4 corresponds to SAPO supernatant, i.e. the cytoplasm of iRBC plus PV content.
Remaining pellets containing intact parasites devoid of host cytosol (SLO treatment) or devoid of host cytosol plus PV content (SAPO treatment)
were washed twice in PBS, further lysed in ice-cold water in presence of protease inhibitors and separated by centrifugation into soluble
fractions (SF, lanes 2 and 5, for the SLO and SAPO treatments, respectively) and membrane fractions (MF, lanes 3 and 6, for the SLO and SAPO
treatments, respectively). Processed samples were separated by SDS-PAGE and blotted with antibodies corresponding to PfA-M1 (A. anti-MAP1
antibodies [6]) and several control markers: anti-PfPV1 antibodies (B), used as PV markers [22], anti-PfBip (C) [21] and anti-PfAldolase (D)
antibodies [15] used as parasite reticulum endoplasmic and cytoplasm markers, respectively. The molecular masses kDa are shown on the left.
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tool to investigate protein trafficking in P. falciparum
[19,33]. Here, BFA treatments were used to investigate
PfA-M1 maturation and trafficking. Synchronized early
ring stages were treated with 5 μM BFA for 19 hours
before parasite harvest and analysis. The immunoblot
analysis (Figure 3A) shows that in BFA-treated parasites
only the p120 form is present in contrast to the control
cultures grown in the presence (E) or absence (O) of
ethanol, the solvent used to solubilize the BFA. In these
latter cultures, as expected, p120, p96 and p68 forms
were present, as previously observed [4]. The immuno-
fluorescence analysis revealed that, in BFA treated para-
sites, PfA-M1 was retained in a compartment close to
the nucleus that appears to be distinct from the com-
partment where exp-2 is retained upon BFA treatment
(Figure 3B). Exp-2 is a protein exported to the PVM
[19,36]. In the control culture, exp-2 was targeted as
expected to the PVM and PfA-M1 was diffuse in the
parasite (but outside the FV) as previously shown [4].
Therefore, it appears that BFA blocks the p120 form
PfA-M1 in a compartment close to the nucleus that
could correspond to the ER, and this blockage prevents
its maturation to the p96 and p68 forms.
The first 30 amino acids of PfA-M1 behave as a non-
cleavable signal peptide
In order to test whether the N-terminal segment of PfA-
M1 behaves as a signal peptide and has the capacity to
target proteins to the ER, this region was fused to a
reporter GFP protein using the Multisite Gateway™ tech-
nology system developed by Van Dooren et al [27] for
Plasmodium. Transfectant parasites express the expected
~32-kDa fusion protein that is entirely associated with
the parasite membrane fraction (Figure 4A). Interest-
ingly, no soluble GFP was cleaved off this construct
(Figure 4A). Live imaging on parasites transfected with
this PfA-M1 [1-30]-GFP construct revealed a pattern
characteristic of ER labelling [27,33] (Figure 4B) that
was confirmed by immuno-fluorescence (Figure 4C).
These results strongly suggest that the N-terminal seg-
ment of PfA-M1 has the capacity to target the protein
to the ER of the parasite. But in the absence of the
downstream PfA-M1 sequence, this protein remains
blocked in the ER and attached to the membrane.
Determination of p96 localization depends on the
concentration of saponin
To further investigate possible behavioural differences
between the three forms of PfA-M1, two series of
experiments were performed using synchronized tropho-
zoite stage parasites. In a first experiment, identical
numbers of iRBC were incubated with increasing con-
centrations of saponin (using 0.04%, 0.08%, 0.1% and to
a maximum of 0.2%) and analysed to detect the three
forms of PfA-M1 (Figure 5). The amount of p120 form
that was released into the saponin supernatant - pre-
sumably from the PV - remained constant while that of
Figure 3 BFA blocks the p120 form of PfA-M1 in a compartment close to the nucleus. Synchronized parasites were treated for 19 hours in
presence of 5 μM BFA (B) or in presence (E) or absence (O) of ethanol, in control cultures. A. Parasites were harvested, isolated by using 0.1%
saponin and soluble fractions were blotted with anti-MAP1 antibodies to detect PfA-M1. The p120 form of PfA-M1 is present in BFA-treated
cultures while p120, p96 and p68 forms are present in both control cultures, E and O. B. BFA-treated (a) and control parasites in presence of
ethanol (c) were analysed by immunofluorescence as previously described [4,6] by using anti-MAP1 antibodies [6] to detect PfA-M1 (red) and a
mouse anti-exp2 [19] serum as positive control (green). Nuclei, stained by using Hoechst 33342 appear in blue. Corresponding phase contrasts
are in (b, d). Scale bar, 5 μm.
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Page 7 of 16Figure 4 PfA-M1 [1-30]-GFP yields a 32-kDa protein strictly associated with the parasite membranes that localizes to the ER. A. Soluble
proteins (lanes 2 and 3) and membrane proteins (lanes 4 and 5) from parasites expressing PfA-M1-GFP chimera (51, lanes 2 and 4) or PfA-M1 [1-
30]-GFP chimera (lanes 3 and 5) were separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted with anti-GFP antibodies as
described in the Methods section. PfA-M1-GFP chimera was detected at ~150-kDa in soluble (lane 2) and membrane (lane 4) fractions of the
parasites while the ~32-kDa PfA-M1 [1-30]-GFP fusion protein is strictly insoluble (lane 5). Note that free soluble GFP is produced from PfA-M1-
GFP chimera (lane 2), but not from PfA-M1 [1-30]-GFP chimera (lane 3). Mw markers in kDa are in lane 1. B. Live imaging of FcB1 parasites
transfected with a construct allowing expression of PfA-M1 [1-30]-GFP chimera. Top row: ring stages; bottom row: young schizont stages. Nuclei
were stained with Hoechst 33342, 4 μg.ml
-1. cc stands for “colour combine”. Scale bar, 5 μm. C. Immuno-fluorescence analysis of FcB1 parasites
transfected with a construct allowing expression of PfA-M1 [1-30]-GFP chimera, fixed by using 3.7% formaldehyde and analysed as previously
described [4,6] by using rabbit anti-PfBip [21](red) and mouse anti-GFP (green) antibodies. Top row: trophozoite stages; bottom row: schizont
stages. Nuclei were stained with Hoechst 33342, 4 μg.ml
-1. cc stands for “colour combine”. Scale bar, 5 μm.
Figure 5 Increasing the concentration of saponin frees p96 but not p68 from pellet to supernatant. Infected erythrocytes at the
trophozoite stage were treated with increasing concentrations of saponin from 0.04% (lanes 1 and 2), 0.08% (lanes 3 and 4), 0.1% (lanes 5 and
6) to 0.2% (lanes 7 and 8), separated into supernatant (SNT, lanes 1, 3, 5, 7) and pellet (P, lanes 2, 4, 6, 8) fractions and immunodetected with
anti-MAP1 antibodies [6](A, B). Antibodies against PfBip [21] were used as controls (C). The amount of p68 (B) and PfBip (C) in the pellet fraction
(parasite) remains constant with increasing concentrations of saponin while the amount of p96 released into the supernatant fraction increases
with the saponin concentration (A).
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Page 8 of 16released p96 progressively increased (see Figures 5A, B).
At the maximum concentration of 0.2% saponin, p96
was exclusively fractionated to the supernatant fraction.
Therefore, at low saponin concentration p96 remains
associated with the parasite fraction, but as the concen-
tration of saponin is increased, p96 shifts to the super-
natant fraction corresponding to the PV. Upon similar
treatment, only a minor proportion of Bip, the ER mar-
ker [21], was released to the supernatant (Figure 5C).
Relative amounts of internal and secreted p120 and p68
In a second experiment, trypsin was added to iRBC after
fractionation with either SLO or saponin prior to
separation by SDS-PAGE andi m m u n o b l o t t i n gu s i n g
anti-MAP1 PfA-M1 antibodies (Figure 6). The trypsin
treatment of saponin-lysed iRBC significantly decreased
the amount of p120 compared to the reduction observed
for the p68 form. In addition, the trypsin treatment after
SLO permeabilization (that leaves the PVM intact) does
not affect the amounts of the p120 protein (nor that of
p68) in the pellet fraction. Densitometric scanning indi-
cated that ~57% of p120 is in the PV and ~43% is inter-
nal as compared to the control PfAldolase (82% internal,
18% in the PV, Figure 6C).
Is PfA-M1trafficked back in the digestive vacuole?
PfA-M1 has been recently reported to be delivered to
the food vacuole (FV) [26]. This result was obtained by
fusing PfA-M1 to the Yellow Fluorescent Protein (YFP)
in stably transfected parasites. Some yellow fluorescence
was indeed somewhat associated with the FV in these
transfected parasites and some fluorescence was also
associated with nuclei [26]. Experiments were designed
to test whether endogenous PfA-M1 was, indeed traf-
ficked to the FV, and specifically in which form. Para-
sites were fractionated as previously described [3,20]
(Figure 7A) and fractions were immuno-detected with
antibodies specific for PfA-M1 and three control marker
proteins (Figure 7B). In these analyses, the majority of
PfPlasmepsin I, a specific marker of the FV [23] was
indeed associated to the pure FV fraction (fraction E,
Figure 7B) as well as some PfA-M1. Densitometric mea-
surements indicated that only 16% of the p68 form of
PfA-M1 was however associated with this FV fraction,
together with traces of p120 and p96 forms, while 40%
of Plasmepsin I was associated with this fraction (Table
1). In this assay, the majority of PfA-M1 was associated
with the soluble fractions, mainly fraction A. PfAldolase,
a cytoplasmic parasite marker [15], was also mainly
Figure 6 Effect of trypsin on p120 and p68. Infected erythrocytes at the trophozoite stage were treated with either SLO (lanes 1, 2, 3) or 0.1%
saponin (SAPO) (lanes 4, 5, 6) and separated into supernatants (SNT, lanes 1 and 4) and pellets (P). Pellets were treated (P+T, lanes 3 and 6) or
not (P-T, lanes 2 and 5) with 500 μg.ml
-1 trypsin for 30 min at room temperature and the reaction was stopped by using trypsin inhibitor (1mg.
ml
-1) for 5 min on ice before separation of samples by SDS-PAGE. Anti-MAP1 antibodies [6]were used to detect PfA-M1 forms, indicated on the
left (A) or PfPV1 (B) and PfAldolase (C) as controls. The amount of p120 relative to p68 was strikingly reduced in SAPO pellets as compared to
SLO pellets, after trypsin treatment.
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Page 9 of 16associated with this soluble fractions, while PfSERP, a
protease associated to the parasitophorous membrane
[18], was as expected mainly associated with fraction C
corresponding to membranes, vacuole, and debris. From
this data, it was deduced that only a minority of PfA-
M1, in the p68 form, was indeed targeted to the FV,
w i t ht h em a j o r i t yo fP f A - M 1b e i n gt a r g e t e dt oo t h e r
locations inside the parasite. Interestingly these values
are in close agreement with the data by Dalal and
Klemba who reported a 20% enrichment of the enzy-
matic activity associated with PfA-M1 in enriched FV
fractions [26].
This marginal delivery of PfA-M1 to the FV was
further investigated by live imaging of erythrocytic
stages of P. falciparum stably expressing a PfA-M1
protein fused to GFP (Figure 8, A to 8C) by following
the procedure described by Klemba et al for Plasmep-
sin II [24]. Live parasite imaging confirmed the expres-
sion of PfA-M1 GPF chimera in rings, trophozoites
and schizonts (Figure 8, D to 8I). In ring stages, the
GFP fluorescence was observed as a circle surrounding
the nucleus (Figure 8D, E); in trophozoites only, some
GFP fluorescence was associated with FV (8G) or more
frequently the nucleus (8F) as described by Dalal and
Klemba [26]. In young schizonts, the GFP fluorescence
associated with the FV compartment was very faint
(Figure 8H). Interestingly, in segmenting schizonts,
strong spots were clearly associated with and between
nuclei. GFP fluorescence was absent from the FV
(Figure 8I). These images are strikingly different from
the images obtained in parasites expressing plasmepsin
II fused to GFP in which the GFP fluorescence was
strongly associated with the FV compartment [24]. It
appears, therefore, that a proportion of the processed
PfA-M1 is delivered to the FV only at trophozoite
stage.
Discussion
The current work is aimed at elucidating behavioural
and localization differences between the different forms
of PfA-M1 as a means to better understand the role(s)
Figure 7 PfA-M1 is minimally associated with FV fractions. A. P. falciparum food vacuole fractions were isolated as shown in the schematic
diagram and in the Methods section. B. Fractions A to F were analysed for the presence of marker proteins. Equivalent amounts of proteins
were loaded for each fraction (corresponding to 4 × 10
7 iRBC per lane), and immunoblotted with anti-MAP1 antibodies [6] to reveal PfA-M1, or
antibodies against Plasmepsin 1 [23](Plas1), PfSERP[18] (SERP) and PfAldolase [15] (Ald) as controls. The numbers on the left indicate Mw in kDa.
The densitometric analysis of these immunoblots is presented as Table 1.
Table 1 Densitometric quantification of PfA-M1 forms
and control proteins
fraction p120 p96 p68 PlasI SERP Aldolase
A 56% 58% 49% 23% 15% 53%
B 10% 9% 8% 7% 25% 25%
C 9% 7% 10% 14% 29% 7%
D 7% 8% 9% 10% 9% 5%
E 10% 10% 16% 40% 17% 5%
F 8% 8% 8% 6% 5% 6%
The p120, p96 and p68 forms of PfA-M1 as compared to Plasmepsin I (PlasI),
SERP and Aldolase were quantified in the six fractions of the FV isolation
procedure. Fractions are as described on Figure 7A, i.e. fractions A and B
corresponding to soluble proteins, fraction C to membranes, vacuoles, debris
and fraction E to pure FV. Bands intensities were obtained by scanning each
column of the Western Blot on Figure 7B. Values are expressed as a % of the
sum of intensities in the six fractions for a given protein.
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shed new light on PfA-M1 biosynthesis and maturation.
The three p120, p96, and p68 soluble forms of the
enzyme were confirmed by using an antibody directed
against the enzyme active site. Using the same antibody,
a similar pattern was observed in Plasmodium berghei
and Plasmodium yoelii soluble protein extracts strongly
suggesting conserved maturation processes for this
enzyme in the Plasmodium genus (I. Florent, personal
communication).
Among these three forms, p120 is the only one that is
found, in part, associated with membrane fractions.
These experimental results fit with the predictions from
the PfA-M1 gene structure: i) both Signal-P [8,10,11]
and PSORT [9,37] predict a single transmembrane
region located at the N-terminus of the mature peptide:
ii) previous studies indicating that p96 and p68 are
indeed devoid of this N-terminal region [4,6]. While Sig-
nal-P predicts that this region does not correspond to a
typical eukaryotic sensu stricto signal peptide - it is
Figure 8 Live imaging of FcB1 parasites transfected with a construct allowing expression of PfA-M1-GFP chimera confirms its
marginal association with the FV. A. Schematic representation of the integration of the PfA-M1-GFP plasmid at the PfA-M1 locus in the P.
falciparum genome. The genomic environment of the PfA-M1 gene (MAL13P1.56) in wild type parasites (wt) is draw to scale with indication of
the two flanking HindIII sites (H). Integration of the PfA-M1-GFP plasmid creates a fused gene and a truncated gene in transfected parasites (51).
The red bar corresponds to the 1024-bp fragment encoding the C-terminal part of PfA-M1 that was cloned in the plasmid and subsequently
used as probe on Southern blots. B. Nuclear DNA from wild type (wt) or transfected parasites (51) was digested by using HindIII, separated on
0.7% agarose gels in 1×TBE, transferred to nylon and hybridized with the [
32P]-labelled 1024-bp fragment as previously described [6]. The
observed pattern indicates, as expected, a wild-type HindIII fragment (Wt, ~8-kb) that is replaced, in transfected parasites (51), by a 5’-fused gene
(~6.8-kb), a 3’-truncated gene (~6.2-kb) and a plasmid (~5-kb) HindIII bands. Note that this pattern is similar to that obtained by Dalal and
Klemba [26]. C. Soluble proteins from transfected parasites (51) were separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted
with anti-GFP (lane 1) or anti-MAP1 [6](lane 3) antibodies as described in the Methods procedures section, revealing the recombinant PfA-M1-
GFP protein, at ~150-kDa and some free GFP. Mw markers in kDa are in lane 2. Mw markers are as described on Figure 4. D to I: live imaging of
transfected parasites showing: D, E. ring stages. F, G, trophozoite stages; H. young schizont. I. segmenting schizont. First column: GFP (green) and
nuclei (Hoechst 33342 staining, 4 μg.ml
-1); second column: phase contrast; third column: overlay. Scale bar, 5 μm.
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cates a classical signal peptide that would encompass
the first 30 amino acids (Additional file 3). The N-term-
inal region has the capacity to drive a downstream pro-
tein to the ER where it remains attached, presumably to
the ER membrane (see the results studying PfA [1-30]-
GFP chimera, Figure 4A, lanes 3 and 5), while the fusion
of the complete PfA-M1 to GFP does not prevent the
cleavage of this N-terminal region. Therefore, some
soluble PfA-M1-GFP chimera is being produced in
transfected parasites (see Figure 4A lane 2).
The p120 form of PfA-M1 targets the enzyme to the PV
via ER and Golgi
Brefeldin A [34,35] which blocks protein trafficking in P.
falciparum for both the classical secretory pathway [33]
and the alternate pathway for proteins destined to
the host cell [31,32] was able to block PfA-M1 under
the p120 form in a parasite compartment close to the
nucleus that could correspond to the ER. Because this
p120 form is mainly soluble and no peptides corre-
sponding to the N-terminal hydrophobic region could
be found by the mass spectrometry analysis of PfA-M1
in the PV, it appears likely that p120 would be cleaved
off this peptide during its transport through ER/Golgi
towards the PV. The PV is believed to be the default
pathway of plasmodial proteins having an N-terminal
signal peptide [33]. The results obtained with the PfA-
M1 [1-30]-GFP chimera indicate that the cleavage of
this PfA-M1 signal peptide would occur at or down-
stream of position 30. The molecular structure and bio-
logical function of the N-terminal domain of PfA-M1 is
currently being further analysed by using GFP-fusions
strategies.
The p96 form of PfA-M1 is an endogenous form of the
enzyme that resides mainly outside of the parasite
The p96 form, thought until now to be an “in vitro
degradation product” of the p120 form [4], was discov-
ered in this current work to be a endogenous form of
the enzyme that resides mainly outside the parasite in
the PV and also in vesicles lysed by high concentrations
of saponin. These properties of p96 are in total agree-
ment with previously published data in which PfA-M1
biochemical studies were focused on parasites isolated
by using 0.2% saponin and extensively washed in pre-
sence of protease inhibitors [4]. Indeed, in these studies,
both the PV compartment and the vesicles sensitive to
saponin were discarded explaining why p96 was not
detected. The discovery that p96 is indeed an endogen-
ous form of PfA-M1 provides the “missing link” between
p120 and p68 forms of PfA-M1 that was extensively stu-
died but never identified [4], and also provides a better
understanding of how PfA-M1 is expressed, trafficked,
and matured in parasites. Importantly, it must be
emphasized that the p96 form of PfA-M1 is truly a
labile form of the enzyme that is difficult to characterize
biochemically. In these studies, the amount of p96 rela-
tive to p120 and p68 varied from one assay to the next,
depending on the concentration of saponin used to iso-
late the parasite and also the age and stage distribution
of these parasites.
The p96 form of PfA-M1 is found within vesicles
In contrast to p120, p96 is within a compartment that
is disrupted by higher concentrations of saponin at the
periphery of the parasite and the PV. Based on pub-
lished electron microscopic and ultrastructure data on
P. falciparum, p96 could be present either in vesicles
being formed at the level of the cytostome or in dou-
b l em e m b r a n es t r u c t u r e st h a th a v eb e e np r e v i o u s l y
described [38]. A logical hypothesis is that, after its
delivery to the PV as the soluble p120 form, PfA-M1 is
processed into the soluble p96 that returns into the
parasite inside vesicles where the p96 to p68 conver-
sion would occur, since p68 is strictly found within the
parasite (Figure 9). Notably, 10,000 g and 100,000 g
centrifugations of parasite extracts have no impact on
the distribution of the different forms of PfA-M1
between soluble and insoluble fractions (I. Florent, per-
sonal communication). As compared to p96, p68 is
devoid of the C-terminal part of PfA-M1 that has been
mapped from position ~803 to the end of the protein
based on Mw predictions from protein sequences (see
Additional file 1). Very interestingly, a peptide of
about 30 kDa corresponding closely to this C-terminal
part (77% coverage from position 807 to 1085 of PfA-
M1) was identified in a proteomic study recently per-
formed to identify Plasmodium proteins specifically
oxidized after chloroquine treatments of parasites [39].
This experimental result indicates that the C-terminal
end of PfA-M1, presumably removed during the p96
to p68 conversion of PfA-M1, is indeed produced in
parasites at least as an oxidized form in chloroquine-
treated schizonts. The parasite compartment in which
this oxidation occurs is not yet identified and will be
the focus of future studies. However, this compartment
appears distantly related to the FV since none of the
known FV haemoglobinases were identified as being
oxidized in this proteomic analysis [39]. Another out-
standing question is whether the C-terminal part of
PfA-M1 that is cleaved from p96 to yield p68 contains
signals necessary for the return of p96 into the para-
site, before its conversion under the p68 form. C-term-
inal signals have recently been identified in P.
falciparum proteins, such FCP protein [40], and it has
been previously noticed that the C-terminal end of
PfA-M1 displays the signature of “microbodies
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under study in the laboratory using GFP chimeras.
What is then the final destination of PfA-M1 and what is
its role in the parasite biology?
While p120 and p96 therefore appear as obligatory inter-
mediate forms allowing proper targeting of p68 in the
parasite, the enigma remains as to where p68, generated
in vesicles from the p96 form, is targeted in the parasite
and which function it performs. As previously men-
tioned, the p68 form corresponds, in terms of size and
domain, to the smallest catalytic domain of M1 family
metallopeptidases [4,41] and was experimentally shown
to be enzymatically active [4]. The hypothesis that PfA-
M1, encoded by a gene conserved through evolution
from bacteria to humans [6] has been retained by the
parasite exclusively to perform the function of a haemo-
globinase is currently challenged by series of biological
data, even if this may be one of its roles [4,6,26,42].
Beside the fact that native PfA-M1 has never been
observed in FV by using immuno-fluorescence micro-
scopy [4,6], in this current study, it does not segregate to
any significant extent with pure FV fractions that do con-
tain Plasmepsin I, a typical endoprotease of this compart-
ment [23]. In addition, the pH at which PfA-M1 is active,
which was measured experimentally, is definitively not
acidic [4] (Additional file 4). An hypothesis that remains
compatible with the observations by Dalal and Klemba
[26] is that PfA-M1 could be directed toward the FV, but
would stop at its border [4], maybe in the cytostomal
vesicles that have recently been shown to have a neutral
pH [43]. These results have important implications
regarding the role that PfA-M1 could perform in the
final steps of haemoglobin digestion recently documented
by using inhibitors [42]. Indeed, rather than being pre-
sent on the cytoplasmic face of the FV, as recently pro-
posed [42,44] and discussed [45], the current study
suggests a presence of PfA-M1 within vesicles. Another
possibility is that PfA-M1 would be directly involved in
vesicular trafficking from the PV towards the FV. In fact,
in mammals and plants some M1 family members have
been shown to be involved in vesicular trafficking. For
example, IRAP (Insulin-regulated glucose transporter)
mediates the trafficking of vesicles laden with glucose to
the plasma membrane [46]. Alternatively, PfA-M1 could
be targeted to many other destinations, such as the
nucleus, as recently proposed by Dalal and Klemba [26]
or even have pleiotropic roles as found for example for
falcilysin [47]. Importantly, it must be noted that the ser-
ies of transcriptomic and proteomic studies performed
on P. falciparum, rodent malaria, and bloodstream and
insect stages all converge towards the fact that PfA-M1
expression is not at all restricted to bloodstream stages
[48-52]. In particular, PfA-M1 was detected in P. falci-
parum gametocytes and gametes [51], in P. falciparum
sporozoites [49,52], and PbA-M1, the orthologue PfA-
M1 in P. berghei was also detected in P. berghei gameto-
cytes and ookinetes [50,53]. Very recently, PfA-M1 was
Figure 9 Proposed model for the trafficking and maturation of PfA-M1 in infected erythrocytes. PfA-M1 is targeted to the secretory
pathway and the trafficking to the Golgi is sensitive to brefeldin A. The p120 is secreted into the vacuolar space where it undergoes proteolytic
processing to yield the p96 form which is endocytosed within the double membrane of the cytostome and taken back into the parasite. The
p96 is further processed to the p68 form which is targeted towards the digestive food vacuole, where it is marginally delivered.
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from oocysts and in sporozoites isolated form salivary
glands [52]. Taken together, these results strongly suggest
the role played by PfA-M1 in the parasite biology is prob-
ably not restricted to haemoglobin digestion in or outside
the FV. Deciphering the complexity of its trafficking and
maturation in infected red blood cells or other parasite
stages is, therefore, of key importance for the further
development of efficient inhibitors against this enzyme
[42,54,55].
Conclusion
In the current study, new biochemical data allowed to bio-
logically differentiate between the three forms of PfA-M1,
p120 being a precursor form of PfA-M1 likely found in
ER, Golgi and PV, p96 being a transient form located in
PV and vesicles, and p68, the final processed form being
yielded in vesicles likely trafficking back from the PV to
the parasite since p68 is exclusively localized within the
parasite. These results bring new insights regarding PfA-
M1 topology and relation to key compartments of the
infected red blood cell in particular relative to the food
vacuole. Indeed, PfA-M1 would reside in the ER, Golgi
and PV and also outside the food vacuole but inside vesi-
cles, or be marginally delivered into the food vacuole at
trophozoite stages, but would not be in direct contact with
the parasite cytoplasm, contrary to the recent proposal
that the membrane form of PfA-M1 would be attached on
the cytoplasmic side of the food vacuole [44]. Such a loca-
lization of PfA-M1 has, therefore, important implications
both for its biological function and for further improve-
ment of established inhibitors against this putative thera-
peutic target [42,54,55].
Additional material
Additional file 1: Structure of the full length PfA-M1 and of the
three p120, p96 and p68 forms. The full length PfA-M1 (top line) is as
predicted from the gene structure [6] and EMBL Y09081.2. It starts with a
24 amino-acids N-terminal hydrophobic domain which is a putative
signal sequence (SS) and terminates with a putative microbodies
targeting signal (NKL) [4,6]. The N and C-termini of p96 and p68 forms
are not clearly defined but their N-termini have been experimentally
shown to be located between the MAP2 (
141SDKMKPYEEGHG
153) and
MAP1 (
192KNEPKIHYRKDYK
205) epitopes [4]. The three p120, p96 and p68
forms are soluble and all contain a full active site (canonical sequence
[GAMEN]-[HExxHx18E]-[Y], [4,41]). The arrow below p68 corresponds to
the PfA-M1 domain expressed as recombinant protein (amino acids 191
to 802).
Additional file 2: anti-p68 and anti-MAP1 antibodies label the same
proteins in parasite extracts. Soluble parasite extracts from
asynchronous cultures were separated by 2D-gel electrophoresis before
western transfer and immunodetection using anti-p68 antibodies (A) and
anti-MAP1 antibodies (B), revealing identical patterns. The ladder above
the gels represents the pH3-pH10 strips used for isoelectricfocussing,
with the various isoelectric points. Molecular weight markers, on the left
of each gel are in kDa. Arrows point to the p120, p96 and p68 forms of
PfA-M1, respectively.
Additional file 3: Conflicting results are yielded by Signal-P and
PSORT analyses. A. PfA-M1 sequence was analyzed by Signal-P by using
“eukaryotic sequence” setting; the output clearly indicates the presence
of a 24 amino acids hydrophobic domain (S-score) but the absence of a
typical cleavage site (C and Y scores). B. PfA-M1 was analysed by PSORT
http://www.psort.org/ and a classical signal peptide encompassing the
30 first amino acids was predicted.
Additional file 4: pH dependency of PfA-M1 enzymatic activity. PfA-
M1 activity (pure native enzyme and L-Leu-AMC substrate) was measured
between pH 4.0 and pH 10.0 and the results are plotted as % of maximal
activity (pH 7.5). This diagram corresponds to a graphical representation
of the experimental data by [4].
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AMC: 7-amido-4-methylcoumarin; BFA: brefeldin A; DIGE: Difference In Gel
Electrophoresis; ER: endoplasmic reticulum; FV: food vacuole; GFP: green
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